Nxera Pharma Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	11,597	20,365	36,203	49,065	66,557	60,087
Cash & Short-Term Investments	11,597	20,365	36,203	49,065	66,557	60,087
Cash Growth	-66.35%	-43.75%	-26.21%	-26.28%	10.77%	50.19%
Accounts Receivable	11,599	7,730	6,695	5,064	2,462	2,138
Other Receivables	2,464	3,867	4,643	6,823	140	103
Receivables	14,063	11,597	11,338	11,887	2,602	2,241
Inventory	11,162	11,294	8,838	2,903	-	-
Prepaid Expenses	-	1,205	1,259	790	638	388
Other Current Assets	2,017	4	217	467	145	92
Total Current Assets	38,839	44,465	57,855	65,112	69,942	62,808
Property, Plant & Equipment	7,250	7,455	7,468	7,900	3,791	3,817
Long-Term Investments	4,078	2,919	4,550	3,308	1,801	6,145
Goodwill	25,556	25,838	25,693	24,623	15,306	-
Other Intangible Assets	53,578	49,230	51,911	52,291	8,577	24,215
Long-Term Deferred Tax Assets	4,014	4,879	4,021	3,964	-	-
Other Long-Term Assets	23	1	-	-	-	-
Total Assets	133,338	134,787	151,498	157,198	99,417	96,985
Accounts Payable	4,904	7,494	4,052	4,244	1,628	1,176
Accrued Expenses	-	568	1,250	-	400	570
Current Portion of Long-Term Debt	5,798	5,798	5,798	5,941	-	-
Current Portion of Leases	898	886	892	832	176	193
Current Income Taxes Payable	22	244	322	4,640	260	279
Current Unearned Revenue	-	2,224	3,141	1,388	1,450	785
Other Current Liabilities	3,245	286	177	140	178	4,188
Total Current Liabilities	14,867	17,500	15,632	17,185	4,092	7,191
Long-Term Debt	45,820	47,189	57,727	63,215	27,981	27,440
Long-Term Leases	3,314	3,506	3,483	3,985	1,577	1,638
Long-Term Deferred Tax Liabilities	135	-	1,857	1,490	2,922	2,706
Other Long-Term Liabilities	5,516	5,595	4,281	4,513	4,909	542
Total Liabilities	69,652	73,790	82,980	90,388	41,481	39,517
Common Stock	47,450	47,450	47,172	46,807	41,335	41,036
Additional Paid-In Capital	22,570	22,120	35,074	34,048	29,525	29,100
Retained Earnings	-15,081	-17,546	-20,942	-16,104	-8,911	-9,768
Treasury Stock	-3	-3	-3	-1	-1	-
Comprehensive Income & Other	8,750	8,976	7,217	2,060	-4,012	-2,900
Total Common Equity	63,686	60,997	68,518	66,810	57,936	57,468
Shareholders' Equity	63,686	60,997	68,518	66,810	57,936	57,468
Total Liabilities & Equity	133,338	134,787	151,498	157,198	99,417	96,985
Total Debt	55,830	57,379	67,900	73,973	29,734	29,271
Net Cash (Debt)	-44,233	-37,014	-31,697	-24,908	36,823	30,816
Net Cash Growth	-	-	-	-	19.49%	31.78%
Net Cash Per Share	-489.17	-410.01	-353.24	-301.85	445.85	375.78
Filing Date Shares Outstanding	90.49	90.49	89.9	89.45	81.92	81.52
Total Common Shares Outstanding	90.49	90.49	89.9	89.45	81.92	81.52
Working Capital	23,972	26,965	42,223	47,927	65,850	55,617
Book Value Per Share	703.75	674.04	762.15	746.93	707.20	704.97
Tangible Book Value	-15,448	-14,071	-9,086	-10,104	34,053	33,253
Tangible Book Value Per Share	-170.71	-155.49	-101.07	-112.96	415.67	407.92
Order Backlog	-	1,929	1,122	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.